Resources to Help Support Your Patients
and Practice This Flu Season

Vaccine Resources for Your Patients

Sanofi Pasteur is committed to supporting your immunization efforts and helping you guide the vaccine discussion with your patients. Here, you’ll find a collection of helpful brochures and resources that provide information about our influenza vaccines.

DIGITAL FLUZONE HIGH-DOSE QUADRIVALENT PATIENT BROCHURE

This brochure can help you talk to your eligible patients 65 and over about Fluzone High-Dose Quadrivalent and why it could be important to receive a high-dose influenza vaccine at their age.

View Here

DIGITAL FLUBLOK QUADRIVALENT PATIENT BROCHURE

This brochure can help you talk to your eligible adult patients about the features of Flublok Quadrivalent and how they may benefit from the protection it offers.

View Here

Vaccine Resources for Your Practice

Sanofi Pasteur is proud to offer a broad portfolio of vaccines to help you meet your immunization goals. Learn more with these useful resources:

CONDENSED PORTFOLIO GUIDE

A simplified overview of our vaccine product portfolio that can be hung on the refrigerator for easy access to dosing presentation, packaging images, and includes a section for practice-specific notes.

View Here

FLUZONE HIGH-DOSE QUADRIVALENT 0.7‑mL FLASHCARD

This resource provides an overview of the packaging for the 0.7-mL presentation for Fluzone High-Dose Quadrivalent.

View Here

To request printed materials, contact your Sanofi Pasteur representative.

Indications

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are vaccines indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone Quadrivalent is approved for use in persons 6 months of age and older. Flublok Quadrivalent is approved for use in persons 18 years of age and older. Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.

Important Safety Information

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Important Safety Information

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent may not protect all recipients.

For Fluzone Quadrivalent, in children 6 months through 35 months of age, the most common injection-site reactions were pain or tenderness, erythema, and swelling; the most common solicited systemic adverse reactions were irritability, abnormal crying, malaise, drowsiness, appetite loss, myalgia, vomiting, and fever. In children 3 years through 8 years of age, the most common injection-site reactions were pain, erythema, and swelling; the most common solicited systemic adverse reactions were myalgia, malaise, and headache. In adults 18 years and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, fatigue, myalgia, and arthralgia. In adults 50 years of age and older, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, and fatigue.

For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent, other adverse reactions may occur.

Before administration, please see the full Prescribing Information for Fluzone Quadrivalent, Flublok Quadrivalent, or Fluzone High-Dose Quadrivalent. Also, please see complete Patient Information for Fluzone Quadrivalent or Fluzone High-Dose Quadrivalent.

MAT-US-2019708-v1.0-05/2021